Evelo Biosciences, Inc.
OTC: EVLO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Craig R. Jalbert
- Employees
- 66
- Headquarters
- Cambridge, United States
- IPO year
- 2018
- Market cap
- $1.9K
- Website
- https://www.evelobio.com
Loading EVLO…
Loading profile data…Frequently asked questions about EVLO
What does Evelo Biosciences, Inc. (EVLO) do?
Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psorias...
Where does EVLO trade?
Evelo Biosciences, Inc. (EVLO) trades on the Other OTC.
What sector is EVLO in?
Evelo Biosciences, Inc. (EVLO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Evelo Biosciences, Inc.?
Craig R. Jalbert is the chief executive officer of Evelo Biosciences, Inc. (EVLO).
Where is Evelo Biosciences, Inc. headquartered?
Evelo Biosciences, Inc. is headquartered in United States.
Does EVLO pay a dividend?
Evelo Biosciences, Inc. (EVLO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EVLO go public?
Evelo Biosciences, Inc. (EVLO) completed its initial public offering in 2018.